Notice of Allowability	Application No.	lo. Applicant(s)	
	09/300,612	LIPPS ET AL.	
	Examiner	Art Unit	
	Padmavathi v Baskar	1645	
The MAILING DATE of this communication ap All claims being allowable, PROSECUTION ON THE MERITS herewith (or previously mailed), a Notice of Allowance (PTOL-1 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT of the Office or upon petition by the applicant. See 37 CFR 1.3	IS (OR REMAINS) CLOSED in t B5) or other appropriate commun RIGHTS. This application is su	this application. If not inclu iication will be mailed in du	ided ie course, THIS
1. This communication is responsive to 12/8/04.			
2. X The allowed claim(s) is/are <u>5, 7, 8, 9, 10, 15 and 16have</u>	e been renumbered as 1-7respec	ctively .	
3. The drawings filed on are accepted by the Exam	iner.		
4. Acknowledgment is made of a claim for foreign priority a) All b) Some* c) None of the: 1. Certified copies of the priority documents he 2. Certified copies of the priority documents he 3. Copies of the certified copies of the priority International Bureau (PCT Rule 17.2(a)). * Certified copies not received:	ave been received. ave been received in Application	No	cation from the
Applicant has THREE MONTHS FROM THE "MAILING DAT noted below. Failure to timely comply will result in ABANDO THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		a reply complying with the r	requirements
5. A SUBSTITUTE OATH OR DECLARATION must be su INFORMAL PATENT APPLICATION (PTO-152) which (NOTICE OF
 CORRECTED DRAWINGS (as "replacement sheets") n (a) including changes required by the Notice of Draftsp 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examin Paper No./Mail Date Identifying indicia such as the application number (see 37 CFI each sheet. Replacement sheet(s) should be labeled as such in the paper No./Mail Date 	erson's Patent Drawing Review er's Amendment / Comment or in R 1.84(c)) should be written on the	n the Office action of drawings in the front (not t	he back) of
7. DEPOSIT OF and/or INFORMATION about the de attached Examiner's comment regarding REQUIREMEN			. Note the
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-94) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/S Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Depos of Biological Material	8) 6. ⊠ Interview Sur Paper No./M B/08), 7. ⊠ Examiner's A	ormal Patent Application (P mmary (PTO-413), lail Date <u>12/14/04</u> mendment/Comment tatement of Reasons for A	llowance
	·	SUPERVISORY PATEN TECHNOLOGY CEN	IT EXAMINE

Application/Control Number: 09/300,612

Art Unit: 1645

DETAILED ACTION

Amendment

1. Applicant's amendment filed on 12/8/04 is acknowledged.

Status of Claims

2. Claims 5 and 9 have been amended

Claims 1-4, 6, 11-14 and 17-19 are canceled.

Claims 5, 7, 8, 9, 10, 15 and 16 are pending in the application.

Examiner's amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR
 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with John Casperson 12/14/04,

Claim 5, line 3, after sample, inserted with – an antibody --

Claim 5, line 4, deleted "a"

Claim 5, line 4, after five, inserted --- consecutive ---

Claim 9, line 3, after antibody, deleted "antibodies"

Claim 9, line 4, deleted "a"

Claim 9, line 4, after five, inserted --- consecutive ---

Claim rejection 35 USC 112, first paragraph withdrawn

4. In view of amendment to the claims, the rejection under 35 USC 112, first paragraph is withdrawn.

Application/Control Number: 09/300,612 Page 3

Art Unit: 1645

5. The claims are drawn to novel methods of detecting a toxin using a novel polypeptide consisting of fifteen amino acid sequence, SEQ.ID.NO: 1. The method uses said polypeptide as a diagnostic tool to identify toxins in an immunoassay since the polypeptide appears to be containing the common epitope that binds to various toxins.

Remarks

6. Claims 5, 7, 8, 9, 10, 15 and 16 are allowed and have been renumbered as 1-7 respectively.

Conclusions

7. Papers related to this application may be submitted to Group 1600, AU 1645 by facsimile transmission. Papers should be transmitted via the PTO Fax Center, which receives transmissions 24 hours a day and 7 days a week. The transmission of such papers by facsimile must conform to the notice published in the Official Gazette, 1096 OG 30, November 15, 1989. The RightFax number for submission of before-final amendments is (703) 872-9306. The RightFax number for submission of after-final amendments is (703) 872-9307.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PMR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PMR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PMR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 09/300,612

telephone number is (571) 272-1600

Art Unit: 1645

Page 4

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Padma Baskar Ph.D., whose telephone number is ((571) 272-0853. A message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday to Friday from 6.30 a.m. to 4.00 p.m. except First Friday of each bi-week.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. Any inquiry of a general nature or relating to

the status of this application or proceeding should be directed to the receptionist whose

Respectfully

Padma Baskar Ph.D.